Insider Analysis From LEK On Tackling China’s EDL Challenge: Navigating The Changes And Planning For Success
This article was originally published in PharmAsia News
Executive Summary
After a review of the newly listed products on China’s Essential Drug List, LEK believes price declines and market access can be managed and continued growth is possible for originator products added to the EDL.